Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cytokinetics (CYTK) Profit After Tax (2016 - 2025)

Cytokinetics (CYTK) has disclosed Profit After Tax for 16 consecutive years, with -$345.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Profit After Tax changed N/A to -$345.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$947.4 million, a N/A change, with the full-year FY2025 number at -$785.0 million, down 33.15% from a year prior.
  • Profit After Tax was -$345.4 million for Q4 2025 at Cytokinetics, down from -$306.2 million in the prior quarter.
  • In the past five years, Profit After Tax ranged from a high of -$19.8 million in Q2 2022 to a low of -$345.4 million in Q4 2025.
  • A 5-year average of -$132.5 million and a median of -$134.4 million in 2025 define the central range for Profit After Tax.
  • Peak YoY movement for Profit After Tax: crashed 2296.41% in 2021, then surged 67.8% in 2022.
  • Cytokinetics' Profit After Tax stood at -$30.6 million in 2021, then plummeted by 349.39% to -$137.4 million in 2022, then grew by 0.35% to -$136.9 million in 2023, then dropped by 17.28% to -$160.5 million in 2024, then crashed by 115.17% to -$345.4 million in 2025.
  • Per Business Quant, the three most recent readings for CYTK's Profit After Tax are -$345.4 million (Q4 2025), -$306.2 million (Q3 2025), and -$134.4 million (Q2 2025).